Ethris
Manufacturing · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Semmelweisstr. 3, Planegg, Bavaria, 8215...Phone Number
+49 8989557880Website
www.ethris.comRevenue
$23.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Ethris
Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, the company is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. The company is rapidly advancing the company's pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients' lives.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ethris your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ethris, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Ethris
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Ethris launches new products
Website visits: Recent activity has been detected on your website
Check out if Ethris is spiking on competitors!
Earning: See what the market has to say on Ethris recently announced quarterly report
Funding: Get notified immidiatlly once Ethris has new funding data
Check if Ethris has recently received funding, and reach out quickly before it becomes old news!
Click to see if Ethris had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Ethris
Find more new buyers
Company Profile Activity
Activity Insights
Ethris is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ethris is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ethris.
Ethris financials insights
Gather financial insights about Ethris, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$28M
2022
Series B
$26.3M
2024
Other Financing Round
$5M
Ethris Tech Stack
A closer look at the technologies used by Ethris
Most Recent Scoops
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Funding
Funding
Funding
Left Company
Management Move
Ethris News & Media
Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the […]Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)--Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris’ comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA), minimal UTR and mRNA maEthris Receives €10M EU4Health Grant
Ethris, a Munich, Germany-based clinical-stage biotechnology company, received a €10M grant from EU4Health. The company intends to allocate the amount of support NoVir, a comprehensive project including several preclinical and clinical studies to evaluate the potential of ETH47, its mRNA-based antiviral therapy. Led by CEO Dr. Carsten Rudolph, Ethris a clinical-stage biotechnology company providing a […] The post Ethris Receives €10M EU4Health Grant appeared first on FinSMEs.Ethris Receives €10 Million EU4Health Grant to Support Clinical Development and Expand Antiviral Applications of Lead mRNA Candidate ETH47
MUNICH--(BUSINESS WIRE)--Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it was awarded a €10 million grant from EU4Health, the EU’s largest health programme committed to a healthier European Union. The funding will support NoVir, a comprehensive project including several preclinical and clinical studies to evaluate the potential of ETH47, Ethris’ lead, first-in-class mRNA-based antiviral therapy. Designed as a b
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ethris
Sign Up For FreeTo access detailed company insights
Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, the company is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formu... Read More
